ClinicalTrials.gg
CompletedNCT02990481Updated Apr 16, 2025

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of TRK-950 and TRK-950 in Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer and Cholangiocarcinoma, sponsored by Toray Industries, Inc. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Toray Industries, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
513th of 865
38 · median 50
Started
2017
with 42 others
Phase 1
245 of 1,123
20 open now
Registered
748th of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 513th largest by enrollment of the 865 interventional ones that give a count, is one of 43 that started in 2017, is one of 245 in phase 1, and was the 748th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

  1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent
  2. To establish the dose of TRK-950 recommended for future phase 2 studies
Read the detailed description

This study is a first-in-human study of TRK-950 in patients with advanced solid tumors and is primarily designed to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of TRK-950 administered via intravenous (IV) infusion once weekly for 3 weeks every 28 days in Arm 1.

Once enrollment in Arm 1 was completed, two dose schedules will be evaluated in Arm 2 to determine the dosing schedule. Up to six (6) patients will be enrolled respectively.

In parallel, to determine anti-tumor activity up to twelve (12) patients will be enrolled in Arm 3.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Carcinomas
  • Colon Cancer
  • Cholangiocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed locally advanced or solid carcinomas in Arm 1
  • Patients with histologically confirmed locally advanced or metastatic colon cancer in Arm 2
  • Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3
  • Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment
  • per 1.1 (primary or metastases)

Exclusion criteria

Exclusion Criteria:

  • Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Pregnant or nursing women
  • Treatment with radiation therapy, surgery, chemotherapy, immunotherapy, or therapy within four weeks prior to study entry
  • Unwillingness or inability to comply with procedures required in this protocol
  • Known active infection with , ,
  • Symptomatic
  • Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
  • Patients who are currently receiving any other investigational agent
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Arm 1 - TRK-950

    * Solid tumor * TRK-950 (Three dose levels will be explored during Arm 1)

    Biological: TRK-950

  • Experimental
    Arm 2 - TRK-950

    * Colon cancer * TRK-950 (Low dose and High dose)

    Biological: TRK-950

  • Experimental
    Arm 3 -TRK-950

    * Cholangiocarcinomas * TRK-950 (Low dose)

    Biological: TRK-950

Interventions

  • BiologicalTRK-950

    Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle

  • BiologicalTRK-950

    Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle

  • BiologicalTRK-950

    Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle

06

What researchers measure

Primary outcomes

  1. Adverse event

    Time frame: through study completion, an average of 1 year

  2. CTCAE version 4.03

    Time frame: through study completion, an average of 1 year

  3. Blood pressure (mmHg)

    Time frame: through study completion, an average of 1 year

  4. Heart rate (bpm)

    Time frame: through study completion, an average of 1 year

  5. Respiratory rate (bpm)

    Time frame: through study completion, an average of 1 year

  6. Temperature (°F or °C)

    Time frame: through study completion, an average of 1 year

  7. Weight (lbs/kg)

    Time frame: through study completion, an average of 1 year

  8. Height (inches/cm)

    Time frame: through study completion, an average of 1 year

  9. Karnofsky performance status

    Time frame: through study completion, an average of 1 year

  10. Electrocardiogram

    Time frame: through study completion, an average of 1 year

  11. Clinical laboratory tests

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Area under the concentration curve(AUC)

    Time frame: through study completion, an average of 1 year

  2. Maximum plasma concentration(Cmax)

    Time frame: through study completion, an average of 1 year

  3. Time to maximum plasma concentration(Tmax)

    Time frame: through study completion, an average of 1 year

  4. Terminal elimination half life(t1/2)

    Time frame: through study completion, an average of 1 year

  5. Total body clearance(CL)

    Time frame: through study completion, an average of 1 year

  6. Apparent volume of distribution(Vd)

    Time frame: through study completion, an average of 1 year

  7. Tumor response rate

    Time frame: through study completion, an average of 1 year

  8. Duration of response

    Time frame: through study completion, an average of 1 year

  9. Time to progression

    Time frame: through study completion, an average of 1 year

  10. Progression free survival

    Time frame: through study completion, an average of 1 year

07

Study locations

3 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • Centre Léon Bérard
    Lyon, 69373, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Sep 2019, 30 months.

Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 30 months is below that.

Counting every sponsor, half of 116 studies reached it within 49 months; a quarter within 32 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2016
First posted
Dec 13, 2016
StartActual
Mar 6, 2017
Primary completionActual
Sep 16, 2019
CompletionActual
Sep 16, 2019
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02990481
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Dec 13, 2016
Start date
Mar 6, 2017
Primary completion
Sep 16, 2019
Completion
Sep 16, 2019
Last update
Apr 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK-950

Start the discussion